Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis achieves regulatory milestone for AMG 334 in migraine prevention with EMA filing acceptance

cphi-onlineJune 23, 2017

Tag: Novartis , EMA , Migraine

PharmaSources Customer Service